Journal
Clinical Genitourinary Cancer
Publication Date
2017
Volume
15
Issue
1
Inclusive Pages
42-52.e8
Document Type
Open Access Publication
DOI
10.1016/j.clgc.2016.07.027
Rights and Permissions
Vogelzang NJ, et al (2017) Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer, 15(1): 42-52.e8 http://dx.doi.org/10.1016/j.clgc.2016.07.027 Copyright 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Vogelzang, Nicholas J.; Coleman, Robert E.; Michalski, Jeff M.; Nilsson, Sten; O'Sullivan, Joe M.; Parker, Christopher; Widmark, Anders; Thuresson, Marcus; Xu, Lei; Germino, Joseph; and Sartor, Oliver, "Hematologic safety of radium-223 dichloride: Baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial." Clinical Genitourinary Cancer. 15, 1. 42-52.e8. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5583
